ArticleBMJ open2022

Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study.

Tomohiro Nishina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.